CYTOKINETICS INC — Director's Dealing 2021

Nov 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTOKINETICS INC (CYTK)
CIK: 0001061983
Period of Report: 2021-11-01

Reporting Person: Cragg David (Chief HR & Admin Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	M	6675	$6.0	Acquired	145379	Direct
2021-11-01	Common Stock	S	6675	$34.8896	Disposed	138704	Direct
2021-11-01	Common Stock	M	18325	$6.0	Acquired	157029	Direct
2021-11-01	Common Stock	S	18325	$34.8896	Disposed	138704	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Incentive Stock Option (right to buy)	$6.0	M	18325	Disposed	2023-03-05	Common Stock (18325)	Direct
2021-11-01	Non-Qualified Stock Option (right to buy)	$6.0	M	6675	Disposed	2023-03-05	Common Stock (6675)	Direct

Footnotes

F1: Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total.

F2: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021.

F3: Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan.